KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Current Assets for 13 consecutive years, with $560.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 11.75% to $560.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $560.6 million, a 11.75% decrease, with the full-year FY2025 number at $560.6 million, down 11.75% from a year prior.
  • Current Assets was $560.6 million for Q4 2025 at Xenon Pharmaceuticals, up from $480.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $794.8 million in Q2 2022 to a low of $256.3 million in Q3 2021.
  • A 5-year average of $552.3 million and a median of $559.8 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 207.52% in 2021, then plummeted 31.48% in 2023.
  • Xenon Pharmaceuticals' Current Assets stood at $559.0 million in 2021, then rose by 7.38% to $600.3 million in 2022, then increased by 7.44% to $645.0 million in 2023, then dropped by 1.5% to $635.3 million in 2024, then decreased by 11.75% to $560.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Current Assets are $560.6 million (Q4 2025), $480.1 million (Q3 2025), and $500.3 million (Q2 2025).